Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystitis, Interstitial | 5 | 2019 | 37 | 3.010 |
Why?
|
| Urinary Bladder | 5 | 2019 | 165 | 2.170 |
Why?
|
| RNA | 7 | 2020 | 89 | 1.590 |
Why?
|
| Gene Expression Profiling | 7 | 2020 | 321 | 1.270 |
Why?
|
| Pelvic Pain | 2 | 2017 | 18 | 1.060 |
Why?
|
| Colitis, Ulcerative | 2 | 2016 | 20 | 1.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2016 | 155 | 0.830 |
Why?
|
| Colon | 2 | 2019 | 56 | 0.790 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 484 | 0.750 |
Why?
|
| Gene Expression | 3 | 2016 | 334 | 0.750 |
Why?
|
| Polyneuropathies | 1 | 2019 | 10 | 0.680 |
Why?
|
| Constipation | 1 | 2019 | 12 | 0.680 |
Why?
|
| Physical Therapy Modalities | 1 | 2019 | 60 | 0.670 |
Why?
|
| Fibromyalgia | 1 | 2019 | 24 | 0.670 |
Why?
|
| Anesthesia | 1 | 2019 | 65 | 0.660 |
Why?
|
| Graft Survival | 1 | 2020 | 228 | 0.640 |
Why?
|
| Ileum | 1 | 2016 | 13 | 0.570 |
Why?
|
| Control Groups | 1 | 2016 | 5 | 0.570 |
Why?
|
| Kidney | 1 | 2020 | 488 | 0.530 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 353 | 0.530 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2013 | 2 | 0.450 |
Why?
|
| RNA, Messenger | 4 | 2006 | 523 | 0.450 |
Why?
|
| Crohn Disease | 1 | 2013 | 25 | 0.440 |
Why?
|
| Female | 10 | 2020 | 18379 | 0.400 |
Why?
|
| Humans | 16 | 2020 | 29556 | 0.390 |
Why?
|
| Adolescent | 4 | 2019 | 3284 | 0.350 |
Why?
|
| Male | 9 | 2020 | 18012 | 0.320 |
Why?
|
| Child, Preschool | 3 | 2019 | 1172 | 0.320 |
Why?
|
| Intestinal Mucosa | 2 | 2019 | 64 | 0.300 |
Why?
|
| Middle Aged | 5 | 2020 | 10936 | 0.300 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 251 | 0.290 |
Why?
|
| Thimerosal | 1 | 2006 | 1 | 0.280 |
Why?
|
| Retrospective Studies | 3 | 2019 | 3144 | 0.280 |
Why?
|
| Autistic Disorder | 1 | 2006 | 6 | 0.280 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2006 | 13 | 0.280 |
Why?
|
| Heat-Shock Proteins | 1 | 2006 | 29 | 0.280 |
Why?
|
| Lymphocytes | 1 | 2006 | 55 | 0.270 |
Why?
|
| alpha-Synuclein | 1 | 2006 | 10 | 0.270 |
Why?
|
| Child | 3 | 2019 | 2234 | 0.270 |
Why?
|
| Young Adult | 3 | 2019 | 2431 | 0.270 |
Why?
|
| Adult | 4 | 2020 | 8528 | 0.260 |
Why?
|
| Oligonucleotides | 1 | 2005 | 28 | 0.260 |
Why?
|
| Primates | 1 | 2005 | 102 | 0.260 |
Why?
|
| Alcoholism | 1 | 2006 | 100 | 0.250 |
Why?
|
| Pilot Projects | 2 | 2016 | 489 | 0.230 |
Why?
|
| Genomics | 1 | 2004 | 82 | 0.220 |
Why?
|
| Proteomics | 1 | 2004 | 92 | 0.220 |
Why?
|
| Pain | 1 | 2004 | 285 | 0.190 |
Why?
|
| Aged | 3 | 2019 | 9590 | 0.190 |
Why?
|
| Delayed Graft Function | 1 | 2020 | 33 | 0.180 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 59 | 0.170 |
Why?
|
| Water | 1 | 2019 | 53 | 0.170 |
Why?
|
| Anesthetics | 1 | 2019 | 19 | 0.170 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3764 | 0.170 |
Why?
|
| Animals | 9 | 2014 | 7339 | 0.160 |
Why?
|
| Cosmic Radiation | 1 | 2018 | 13 | 0.160 |
Why?
|
| Hematopoiesis | 1 | 2018 | 34 | 0.160 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 115 | 0.150 |
Why?
|
| Compliance | 1 | 2017 | 12 | 0.150 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 60 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2016 | 85 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 23 | 0.140 |
Why?
|
| Organ Size | 1 | 2017 | 196 | 0.140 |
Why?
|
| ROC Curve | 1 | 2016 | 149 | 0.140 |
Why?
|
| Urine | 1 | 2017 | 59 | 0.140 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2018 | 166 | 0.140 |
Why?
|
| Cadaver | 1 | 2016 | 145 | 0.140 |
Why?
|
| Macaca fascicularis | 3 | 2006 | 389 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2016 | 270 | 0.130 |
Why?
|
| Inflammation | 1 | 2019 | 511 | 0.130 |
Why?
|
| Prognosis | 1 | 2019 | 1372 | 0.130 |
Why?
|
| Neuromuscular Diseases | 1 | 2014 | 14 | 0.120 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2014 | 14 | 0.120 |
Why?
|
| Sweden | 1 | 2014 | 14 | 0.120 |
Why?
|
| Microarray Analysis | 1 | 2014 | 19 | 0.120 |
Why?
|
| Cystoscopy | 1 | 2014 | 26 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2016 | 861 | 0.120 |
Why?
|
| Syndrome | 1 | 2014 | 66 | 0.120 |
Why?
|
| Biopsy | 1 | 2014 | 243 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2014 | 372 | 0.110 |
Why?
|
| Phenotype | 1 | 2014 | 633 | 0.100 |
Why?
|
| Regenerative Medicine | 1 | 2014 | 192 | 0.100 |
Why?
|
| Prevalence | 1 | 2014 | 910 | 0.100 |
Why?
|
| Risk Factors | 1 | 2017 | 3600 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2014 | 2046 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2124 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2013 | 1701 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2006 | 803 | 0.070 |
Why?
|
| Databases, Genetic | 1 | 2006 | 35 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2004 | 138 | 0.070 |
Why?
|
| DNA Primers | 2 | 2003 | 90 | 0.070 |
Why?
|
| Zinc | 1 | 2006 | 32 | 0.070 |
Why?
|
| Cerebellum | 1 | 2005 | 29 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2006 | 183 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 192 | 0.060 |
Why?
|
| Self Administration | 1 | 2006 | 297 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 643 | 0.060 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 12 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 16 | 0.060 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2004 | 26 | 0.060 |
Why?
|
| Parthenogenesis | 1 | 2003 | 7 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 93 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2004 | 124 | 0.060 |
Why?
|
| Pluripotent Stem Cells | 1 | 2003 | 18 | 0.060 |
Why?
|
| Time Factors | 2 | 2006 | 2014 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2003 | 12 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2003 | 19 | 0.050 |
Why?
|
| Methylmercury Compounds | 1 | 2002 | 7 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 118 | 0.050 |
Why?
|
| Phospholipases A | 1 | 2002 | 28 | 0.050 |
Why?
|
| Arachidonic Acids | 1 | 2002 | 23 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2005 | 248 | 0.050 |
Why?
|
| Astrocytes | 1 | 2002 | 49 | 0.050 |
Why?
|
| Rats | 2 | 2003 | 1609 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 533 | 0.050 |
Why?
|
| Solar Energy | 1 | 2018 | 4 | 0.040 |
Why?
|
| Bystander Effect | 1 | 2018 | 6 | 0.040 |
Why?
|
| Protons | 1 | 2018 | 23 | 0.040 |
Why?
|
| DNA Damage | 1 | 2018 | 88 | 0.040 |
Why?
|
| Iron | 1 | 2018 | 113 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2014 | 31 | 0.030 |
Why?
|
| Bioengineering | 1 | 2014 | 67 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 133 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 203 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2014 | 3128 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2003 | 5 | 0.010 |
Why?
|
| Blastocyst | 1 | 2003 | 8 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 2003 | 4 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 9 | 0.010 |
Why?
|
| Intermediate Filament Proteins | 1 | 2003 | 10 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2003 | 68 | 0.010 |
Why?
|
| DNA Probes | 1 | 2003 | 18 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2003 | 18 | 0.010 |
Why?
|
| Stearic Acids | 1 | 2002 | 5 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 2002 | 22 | 0.010 |
Why?
|
| Phospholipids | 1 | 2002 | 27 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 130 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2002 | 111 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 456 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 209 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 168 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 438 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 748 | 0.010 |
Why?
|
| Neurons | 1 | 2003 | 395 | 0.010 |
Why?
|